Study guide

11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH

Advanced Oncology Certified Nurse Practitioner AOCNP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide

2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening

2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling

3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging

3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment

4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship

4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence

5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy

5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring

6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies

6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology

7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy

7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies

8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response

8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)

9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety

9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions

10 Chapter 10: Supportive Care - Symptom & Comorbidity Management

10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management

11 Chapter 11: Oncologic Emergencies

11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH

12 Chapter 12: Psychosocial Issues

12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources

13 Chapter 13: Professional Practice & Roles of the APRN

13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education

11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH

Key Takeaways Explain This Topic AI

Disseminated intravascular coagulation is diagnosed by the combination of thrombocytopenia, prolonged PT and aPTT, low fibrinogen, and markedly elevated D-dimer, and the definitive treatment is control of the underlying cause.

Acute promyelocytic leukemia presents with DIC and is a true emergency: all-trans retinoic acid is started on clinical suspicion before genetic confirmation, because early hemorrhagic death is the leading cause of treatment failure.

Leukostasis is a clinical syndrome of respiratory and neurologic dysfunction from a blast count usually above 100,000/µL in acute myeloid leukemia, and red cell transfusion should be avoided before cytoreduction because it raises whole-blood viscosity.

Hyperviscosity syndrome from Waldenstrom macroglobulinemia or high-secretory myeloma presents with mucosal bleeding, visual change with sausage-link retinal veins, and neurologic symptoms, and is treated with urgent plasmapheresis.

Serum sodium in SIADH should not be corrected faster than about 8 mEq/L in 24 hours because of the risk of osmotic demyelination syndrome.

Last updated: August 2026

11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH

Blueprint focus: ONCC Domain III — completing the emergency set. These four syndromes account for a disproportionate share of early mortality in hematologic malignancy and small cell lung cancer.

1. Disseminated Intravascular Coagulation (DIC)

Etiology. Systemic activation of coagulation consumes platelets and clotting factors while activating fibrinolysis, producing simultaneous thrombosis and bleeding . Triggers in oncology are acute promyelocytic leukemia (APL) , other acute leukemias, mucin-secreting adenocarcinomas (pancreas, stomach, prostate, lung), and — most commonly overall — sepsis .

Assessment.

  • Test Finding in DIC
  • Platelet count Low and falling
  • Prothrombin time and aPTT Prolonged
  • Fibrinogen Low — an acute-phase reactant, so a normal value in a septic patient may already represent a fall
  • D-dimer / fibrin degradation products Markedly elevated
  • Peripheral smear Schistocytes
  • Antithrombin III Reduced

Clinically: oozing from venipuncture sites, mucosal and gastrointestinal bleeding, petechiae and ecchymoses, and simultaneously acral cyanosis, digital ischemia, or organ infarction.

Management.

Treat the underlying cause. Nothing else is definitive — antimicrobials for sepsis, chemotherapy for the leukemia.

Blood product support guided by bleeding, not by numbers alone. Platelets for a count below roughly 50,000/µL with bleeding (or below 20,000 to 30,000/µL prophylactically in this setting), cryoprecipitate for fibrinogen below approximately 100 to 150 mg/dL, and fresh frozen plasma for prolonged PT and aPTT with bleeding.

Heparin is reserved for the thrombosis-predominant phenotype — digital ischemia, large-vessel thrombosis — and is dangerous in the bleeding-predominant phenotype.

Antifibrinolytics such as tranexamic acid are generally avoided in DIC because they can precipitate catastrophic thrombosis; APL is a specific exception managed by hematology.

The APL emergency

Acute promyelocytic leukemia deserves its own line. The classic presentation is a new acute leukemia with DIC and bleeding , and early hemorrhagic death — often intracranial or pulmonary — is the leading cause of treatment failure. All-trans retinoic acid (ATRA) is started immediately on clinical suspicion , before PML-RARA confirmation returns, because ATRA rapidly reverses the coagulopathy. Aggressive product support targets a fibrinogen above about 150 mg/dL and platelets above 30,000 to 50,000/µL. Watch for differentiation syndrome — fever, dyspnea, hypoxemia, pulmonary infiltrates, weight gain, hypotension, and effusions — treated with dexamethasone 10 mg twice daily started at first suspicion.

2. Hyperleukocytosis and Leukostasis

Definitions. Hyperleukocytosis is a laboratory finding, usually a white cell count above 100,000/µL. Leukostasis is the clinical syndrome that follows when leukemic blasts — which are large, stiff, and adhesive — plug the microvasculature.

Risk. Highest in acute myeloid leukemia , particularly monocytic subtypes, where symptoms can appear above roughly 50,000 to 100,000/µL. Chronic lymphocytic leukemia can reach counts above 300,000/µL without leukostasis, because small mature lymphocytes are far less obstructive.

Presentation.

Pulmonary: dyspnea, hypoxemia often out of proportion to the chest radiograph, diffuse infiltrates.

Neurologic: headache, confusion, visual change, tinnitus, focal deficit, retinal hemorrhage, and in severe cases intracranial hemorrhage.

Fever without documented infection, priapism, and limb ischemia.

Frequently accompanied by DIC and tumor lysis syndrome .

Management.

Aggressive intravenous hydration.

Emergent cytoreduction: induction chemotherapy is the definitive treatment; hydroxyurea provides rapid interim control; leukapheresis may be used for severe symptomatic leukostasis, though it does not improve long-term outcome and is not a substitute for chemotherapy.

Tumor lysis prophylaxis with rasburicase or allopurinol and hydration.

Avoid red cell transfusion until after cytoreduction unless the patient is critically anemic — adding red cells raises whole-blood viscosity and can worsen leukostasis. This is the classic exam trap.

Diuretics are avoided because hemoconcentration worsens viscosity.

3. Hyperviscosity Syndrome

Etiology. A large paraprotein load raising serum viscosity. Waldenström macroglobulinemia (pentameric IgM, which is confined to plasma and highly viscous) is the archetype; IgA and IgG3 myeloma are less common causes. Polycythemia vera and severe leukocytosis raise viscosity by different mechanisms.

Classic triad.

Mucosal bleeding — epistaxis, gingival bleeding, gastrointestinal bleeding.

Visual change — blurred vision or vision loss, with dilated, tortuous, sausage-link retinal veins , papilledema, and retinal hemorrhage on funduscopy. Funduscopic examination is a fast bedside confirmation.

Neurologic symptoms — headache, vertigo, tinnitus, ataxia, confusion, seizure, and rarely coma.

Congestive heart failure from expanded plasma volume may accompany it.

Management.

Urgent plasmapheresis rapidly removes the paraprotein and reverses symptoms. It is the immediate intervention.

Definitive control requires systemic therapy for the underlying plasma cell or lymphoplasmacytic disorder.

Avoid red cell transfusion before plasmapheresis — it raises viscosity further, and this is an exact parallel to the leukostasis rule.

Rituximab in Waldenström macroglobulinemia can cause an IgM flare that transiently worsens hyperviscosity, so plasmapheresis often precedes it.

4. Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

Etiology. Ectopic ADH production, most classically by small cell lung cancer , and also by head and neck cancers, CNS disease, pulmonary infection, and a long list of drugs including cyclophosphamide, vincristine, vinblastine, cisplatin, and SSRIs .

Diagnostic profile.

  • Parameter Finding
  • Serum sodium Low (hyponatremia)
  • Serum osmolality Low (< 275 mOsm/kg)
  • Urine osmolality Inappropriately high (> 100 mOsm/kg)
  • Urine sodium Elevated (> 30 to 40 mEq/L)
  • Volume status Euvolemic — no edema and no orthostasis
  • Thyroid, adrenal, renal function Normal (must be excluded)

Euvolemia is what separates SIADH from hypovolemic hyponatremia (vomiting, diuretics, adrenal insufficiency) and hypervolemic hyponatremia (heart failure, cirrhosis).

Presentation. Severity tracks both the sodium level and the speed of the fall : anorexia, nausea, headache, and lethargy at moderate levels; confusion, seizure, and coma below roughly 120 mEq/L or with rapid decline.

Management.

Asymptomatic or mild: fluid restriction, commonly 500 to 1,000 mL per day, plus increased dietary salt and protein. Treat the malignancy — SIADH from small cell lung cancer often resolves with effective chemotherapy.

Severe symptomatic hyponatremia (seizure, coma): hypertonic 3% saline in small boluses with frequent sodium monitoring in a monitored setting.

The correction-rate rule: do not raise serum sodium faster than approximately 8 mEq/L in 24 hours (some guidance permits up to 10 to 12 mEq/L, with 8 as the safer working target, and a lower limit in high-risk patients). Over-rapid correction causes osmotic demyelination syndrome , presenting days later with dysarthria, dysphagia, quadriparesis, and locked-in syndrome. It is irreversible.

Tolvaptan and other vasopressin receptor antagonists are options for persistent SIADH but require inpatient initiation with sodium monitoring, carry hepatotoxicity limits on duration, and must not be combined with fluid restriction during initiation.

Demeclocycline is a rarely used alternative with slow onset.

Loading diagram... Hematologic and Endocrine Emergency Recognition and First Actions